Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent progress in targeted therapy for non-small cell lung cancer
Yanxia Xiao, Pu Liu, Jie Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer, Bailey G Fitzgerald, Luís Paz-Ares, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 803-822
Closed Access | Times Cited: 36
Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer
Jiexi Wen, Jie Zeng Yu, Catherine Liu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2044-2044
Open Access | Times Cited: 7
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action
May-Lucie Meyer, S. Peters, Tony Mok, et al.
Annals of Oncology (2024)
Closed Access | Times Cited: 6
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Stimulator of Interferon Genes Signal in Lung Cancer Regulates Differentiation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Via the Interferon Regulatory Factor 3/NF-κB Pathway
Jiaojiao Ren, Jun Ying, H Liu, et al.
Journal of Interferon & Cytokine Research (2025)
Closed Access
Gene expression profiling to uncover prognostic and therapeutic targets in colon cancer, combined with docking and dynamics studies to discover potent anticancer inhibitor
Mohammad Kashif
Computational Biology and Chemistry (2025) Vol. 115, pp. 108349-108349
Closed Access
Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma
Zi‐Lu Chen, Kun Mei, Fraser Elisabeth Tan, et al.
Cancer Drug Resistance (2025)
Open Access
Total nutritional double emulsion-based supplement enriched with low-molecular-weight oyster peptides: A promising nutritional strategy for alleviating cachexia in chemotherapy-treated Lewis lung cancer mice
Jinzhen Li, Wenhong Cao, Zhongqin Chen, et al.
Food Bioscience (2025), pp. 105968-105968
Closed Access
NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives
Kareem S. Tahayneh, Mayar Idkedek, Firas Abu Akar
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1025-1025
Open Access
Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment
Ran Cui, Hong Su, Yan Jiang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies
Jiaqi Li, Lim Yi Shen Justin, Jie Qing Eu, et al.
Antioxidants and Redox Signaling (2024) Vol. 41, Iss. 4-6, pp. 322-341
Closed Access | Times Cited: 4
Oral targeted therapy for the treatment of non–small cell lung carcinoma
William J. Phillips, Natasha B. Leighl, Normand Blais, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 16, pp. E558-E561
Open Access | Times Cited: 4
Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC
Xuebao Wang, Ying Lu, Siyu Chen, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107500-107500
Closed Access | Times Cited: 4
Exosomal miR-21 determines lung-to-brain metastasis specificity through the DGKB/ERK axis within the tumor microenvironment
Tung-Yu Tiong, M. Ete Chan, Chun‐Hua Wang, et al.
Life Sciences (2023) Vol. 329, pp. 121945-121945
Closed Access | Times Cited: 10
Cross-attention enables deep learning on limited omics-imaging-clinical data of 130 lung cancer patients
Suraj Verma, Giuseppe Magazzù, Noushin Eftekhari, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 7, pp. 100817-100817
Open Access | Times Cited: 2
Synthesis, characterization and biological research of novel 2-(quinoline-4-carbonyl)hydrazide-acrylamide hybrids as potential anticancer agents on MCF-7 breast carcinoma cells by targeting EGFR-TK
Hany M. Abd El‐Lateef, Duaa Bafail, Noura Hamdi Yousef Alhalees, et al.
RSC Advances (2024) Vol. 14, Iss. 32, pp. 23495-23504
Open Access | Times Cited: 2
The molecular features of lung cancer stem cells (LCSCs) in dedifferentiation process-driven epigenetic alterations
Valentina Masciale, Federico Banchelli, Giulia Grisendi, et al.
Journal of Biological Chemistry (2024), pp. 107994-107994
Open Access | Times Cited: 2
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
Sun Min Lim, Jii Bum Lee, Yuko Oya, et al.
JCO Oncology Practice (2023) Vol. 20, Iss. 1, pp. 47-56
Closed Access | Times Cited: 5
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
Débora Dummer Meira, Maria Clara de Castro e Caetano, Matheus Correia Casotti, et al.
Genes (2023) Vol. 14, Iss. 10, pp. 1906-1906
Open Access | Times Cited: 5
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma
Vlastimil Kulda, Jiří Polívka, Martin Svatoň, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 404-411
Open Access | Times Cited: 4
Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer
Giulia Maria Stella, Sara Lettieri, Davide Piloni, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 1042-1042
Open Access | Times Cited: 4
Roles of Rictor alterations in gastrointestinal tumors (Review)
Ruizhen Cao, Shuilong Guo, Li Min, et al.
Oncology Reports (2024) Vol. 51, Iss. 2
Open Access | Times Cited: 1
Combination therapy of metformin and atorvastatin against benzopyrene-induced lung cancer via inflammatory signaling pathway
Xuecong Ning, Shusen Zhang, Zhiguo Gao, et al.
General Physiology and Biophysics (2024) Vol. 43, Iss. 01, pp. 57-71
Open Access | Times Cited: 1
Agnostic drug development revisited
Alberto Hernando‐Calvo, Alice Rossi, María Vieito, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102747-102747
Closed Access | Times Cited: 1
Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment
Huijuan Mu, Xing Yang, Yanxia Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top